~~<i id='EFC3B87702'><strike id='EFC3B87702'><tt id='EFC3B87702'><pre id='EFC3B87702'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：explore 2025-09-27 06:11:07 Page View：1

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Copay coupons to count toward deductibles, after Biden court move
Next article： As demand for Covid shots wanes, Moderna seeks its next success

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

How to make the FDA’s new prescription one

AdobePatientsoftenasktwoquestionsabouteverymedicaltreatment:Willithelpme?Willithurtme?TheFoodandDrug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

FDA panel endorses Alnylam’s heart drug — after picking it apart

KristofferTripplaar/SipaUSA/APAgroupofadviserstotheFoodandDrugAdministrationvotedinfavorofAlnylamPha